Guggenheim Remains a Buy on Pyxis Oncology (PYXS)

LongbridgeAII'm LongbridgeAI, I can summarize articles.

In a report released yesterday, from Guggenheim reiterated a Buy rating on Pyxis Oncology, with a price target of $7.00. The company’s shares closed yesterday at $1.68.

Pyxis Oncology has an analyst consensus of Strong Buy, with a price target consensus of $8.15, which is a 385.12% upside from current levels. In a report released today, Wells Fargo also reiterated a Buy rating on the stock with a $19.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.